Sillajen's "SJ-650" Research Paper Selected for BRIC's "Koreans Who Are Brightening Korea and the World"

Selected by Top Global Journal Molecular Therapy

Sillajen announced on the 23rd that a research paper on its systemic injectable oncolytic virus platform "SJ-650" has been selected by the Biological Research Information Center (BRIC) for inclusion in "Koreans Who Are Brightening Korea and the World (Hanbitsa)." The Biological Research Information Center (BRIC) introduces Korean scientists who have submitted papers to life science-related SCI journals with an impact factor (IF) of 10 or higher, whose authority is recognized worldwide, along with their papers.

SJ-650 is a technology that overcomes the limitations of existing oncolytic virus therapies, whose efficacy has been restricted because they are rapidly cleared by the complement system and neutralizing antibodies in the body when administered intravenously. It is a systemic injectable oncolytic virus platform designed to express the complement regulatory protein CD55 on the viral surface, enabling it to stably reach tumor tissues even within the host immune environment.

The SJ-650 research paper, jointly conducted by Sillajen researchers and the research team of Professor Lee Dongseop at Seoul National University College of Medicine, was accepted in January by Molecular Therapy, one of the world’s most prestigious journals. Molecular Therapy is the official journal of the American Society of Gene and Cell Therapy (ASGCT) and is a top-tier journal in the field of gene and cell therapy published by the global science publisher Cell Press. Its impact factor (IF) exceeds 12.

The accepted paper is titled "CD55-displaying oncolytic vaccinia virus treated metastatic cancers by evading the effect of host innate and adaptive humoral responses." The core of the paper is that SJ-650 selectively accumulates in tumor tissues and induces tumor cell death even in an environment where neutralizing antibodies are present, and that it demonstrates meaningful antitumor efficacy in metastatic cancer models. Although the final release schedule by Molecular Therapy has not yet been confirmed, the paper is expected to be released next month.

A Sillajen official stated, "We are encouraged that the SJ-650 research paper has been selected as a recommended paper for BRIC's 'Koreans Who Are Brightening Korea and the World' following its acceptance by a global journal," adding, "We expect that the publication of the Molecular Therapy paper, which is anticipated next month, will help showcase the excellence of SJ-650 to global cancer researchers."